Quoin Pharmaceuticals, Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
QNRX Nasdaq 2830 quoinpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases - Jun 26th, 2025 6:30 am
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome - Jun 24th, 2025 6:30 am
QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further - May 28th, 2025 7:13 am
Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study - May 22nd, 2025 6:07 am
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study - May 22nd, 2025 5:30 am
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome - May 20th, 2025 5:30 am
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study - May 14th, 2025 5:30 am
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results - May 13th, 2025 6:00 am
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025 - May 6th, 2025 6:00 am
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule - Apr 30th, 2025 5:30 am
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign - Apr 10th, 2025 5:30 am
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient - Apr 2nd, 2025 5:30 am
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases - Mar 25th, 2025 5:30 am
QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26 - Mar 17th, 2025 8:10 am
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - Mar 13th, 2025 5:30 am
Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025 - Mar 6th, 2025 6:00 am
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease - Mar 5th, 2025 8:16 am
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications - Mar 4th, 2025 5:30 am
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study - Feb 27th, 2025 5:30 am
Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome - Feb 25th, 2025 5:30 am